Genetic Polymorphisms Impact the Risk of Acute Rejection in Pediatric Heart Transplantation: A Multi-Institutional Study

Abstract

This is the largest multicenter study to document the impact of genetic polymorphism combinations on PHTx recipients' outcome. The high proinflammatory (VEGF high/IL-6 high) and lower regulatory (IL-10 low) cytokine gene polymorphism profile exhibited increased risk for late rejection, irrespective of age and race/ethnicity.

Decline in rejection in the first year after pediatric cardiac transplantation: A multi-institutional study

“…Indeed, recent data suggest that there may be a complex interplay between patients' genetic polymorphisms and rejection. 14,15 Thus, there may be intrinsic patient-specific factors that pre-dispose transplant recipients to these more severe episodes of rejection that are not ascertained in our data. Further study is necessary into the array of factors that influence the profile of rejection within a population.…”

Outcomes of Children With Restrictive Cardiomyopathy Listed for Heart Transplant: A Multi-institutional Study

“…16 A recent publication that focused on the effect of genetic polymorphisms found that black race had a higher risk of rejection after transplant in children. 17 More study in this area is warranted. Additionally, an era-effect was seen, with earlier year of transplant carrying a 4-fold increased relative risk of death after transplant.…”

Genetic polymorphisms influence mycophenolate mofetil–related adverse events in pediatric heart transplant patients

“…The findings presented represent pilot data that are being extended to our larger multicenter pediatric heart transplant study of the impact of genetic polymorphisms on graft and patient outcomes in Ͼ500 patients enrolled at six study sites. 43,44 Investigation into the impact of genetic polymorphisms on the efficacy of MMF in heart transplantation is also warranted. The ultimate goal of identifying the genetic, clinical and demographic risk factors of MMF tolerability and efficacy is to tailor immunosuppressive therapy to individual patient needs and risk factor profiles.…”